For years, we’ve been shown research projects teasing next-generation exoskeletons designed to empower those without the use of their legs. But those desiring the devices have been forced to wait for a viable commercial solution — until now
That wait finally ended last week when the United States Food and Drug Administration approved ReWalk Robotics‘ personal exoskeleton for marketing in the U.S.
“Innovative devices such as ReWalk go a long way towards helping individuals with spinal cord injuries gain some mobility,” Christy Foreman, director of the Office of Device Evaluation at the FDAs Center for Devices and Radiological Health, said in a statement.